Munir Pirmohamed

Apr 8, 2024 | ascpt.onlinelibrary.wiley.com | Simon Maskell |Isobel Anderson |Munir Pirmohamed |Elpida Kontsioti

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Recent efforts in pharmacovigilance integrated systems pharmacology into signal detection for single drugs, but not in the context of drug–drug interactions (DDIs). WHAT QUESTION DID THIS STUDY ADDRESS?

Feb 23, 2024 | agsjournals.onlinelibrary.wiley.com | Lauren Walker |Munir Pirmohamed

Key points People in the United Kingdom are living longer with multiple long-term health conditions for which they take many medicines. There is a pivotal need to address aging physiology and multimorbidity in clinical trials and to involve trial participants that mirror the ultimate recipients of a drug during all stages of drug development.

May 31, 2023 | dtb.bmj.com | Lauren Walker |Munir Pirmohamed

Increasing trend in hospitalisation due to adverse drug reactions: can we stem the tide? Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

May 16, 2023 | dtb.bmj.com | Lauren Walker |Munir Pirmohamed

Lauren E Walker, Munir PirmohamedWolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UKCorrespondence to Dr Lauren E Walker, Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, Merseyside, UK; md0u10pc{at}liverpool.ac.uk AbstractLiving with multiple long-term health conditions (multimorbidity) is increasingly common in older age. The more long-term conditions that an individual has, the more medicines they are likely to take.

Jan 27, 2023 | nature.com | Munir Pirmohamed

AbstractInter-individual variability in drug response, be it efficacy or safety, is common and likely to become an increasing problem globally given the growing elderly population requiring treatment. Reasons for this inter-individual variability include genomic factors, an area of study called pharmacogenomics.